Nvidia’s chief executive, Jensen Huang, declared on March 17, 2026, that orders for Chinese firms for the chipmaker’s H200 processors had resumed after a 17-month government-imposed deadlock. The news sent shares of OpenClaw, a Chinese AI startup, surging 23% on speculation its OpenClaw agents—a rival to OpenAI’s GPT systems—were poised to outperform existing models with U.S. hardware. This marks the first concrete trade in a geopolitical chess game that has cost Nvidia $5.5 billion in stranded inventory and U.S. regulators $250 million in a cut from December’s H200 deals.
The context is a decade-long regulatory war over AI dominance. Washington’s export controls, initially imposed in 2024, sought to stymie China’s access to hardware critical for training large language models. Beijing retaliated with tariffs and an aggressive push to fund domestic chipmakers and AI agents. OpenClaw embodies this strategy: its platform, developed with state subsidies, already powers 300,000 productivity tools across Chinese SMEs. The H200’s 128H TeraFLOPs offer OpenClaw’s developers a tool to leapfrog rival frameworks like DeepSeek, which earlier this year triggered an AI-sector rout on Wall Street (per January 2025 *Wall Street Journal* reports).
CNBC and Reuters sources confirm internal preparations for H200 shipments—including a “restart of manufacturing” and “Groq chip adaptations”—that diverge from Bloomberg’s focus on OpenClaw’s stock trajectory. Huang’s insistence that approvals came from “both sides” glosses over the U.S. demand for 25% of sale profits, a financial concession absent in reporting from Beijing-based outlets. Meanwhile, Financial Times coverage frames OpenClaw’s success as a local government-led “productivity gains” project, overlooking the dependency on foreign semiconductors.
The second-order risks for Nvidia are profound. While it forecasts 77% quarterly revenue growth even excluding China, the H200’s return to the market could cannibalize its own Blackwell chip, slated for mass deployment in 2027. More critically, the chipmaker’s reliance on Chinese regulators to greenlight sales underscores the fragility of its business model: Huang’s “restart” announcement arrives as Chinese cybersecurity agencies reportedly delay approvals beyond initial 60-day windows, mirroring tactics that stranded previous shipments.
Unanswered questions persist: What’s the effective capacity of these new H200 sales? How much of OpenClaw’s recent codebase was trained on pre-2024 U.S. hardware? And crucially, who will bear the cost when U.S. regulators—still wary of data exfiltration—impose third-party audits on every transaction?
The next major trigger occurs in June 2026, when both the U.S. and China are scheduled to review export control policies. If Washington reclassifies AI agents as “military technology,” sales could halt again. For OpenClaw, the window to scale its models may prove narrower than investors estimate.